How Did a Tennessee Hospital Give Potassium Instead of Anesthetic to Four Surgery Patients?

Yes, the disturbing Tennessee hospital story circulating online is substantially real. But several of its most viral details are wrong.

On August 14, 2026, four patients undergoing joint-replacement procedures at Ascension Saint Thomas Hospital Midtown in Nashville received the wrong medication because of an error in the hospital pharmacy.

Ascension has now confirmed what the patients were supposed to receive and what they actually received: mepivacaine, a local anesthetic, was mistakenly replaced with potassium phosphate.

All four patients suffered adverse health reactions and required immediate medical care. Local investigative reporting says at least two patients were left paralyzed. One of them, 72-year-old Glenda Dorton, had gone to the hospital for a knee replacement and was subsequently reported by her family to have paralysis from approximately the chest down.

But that is not quite the story millions of people are now encountering online.

Early reports said patients were injected with potassium chloride, sometimes described dramatically as a “lethal injection drug,” instead of bupivacaine. Some posts imply that four doctors individually made the same error or that all four patients have been confirmed permanently paralyzed.

The hospital’s later and more detailed account contradicts important parts of that narrative.

The confirmed medication was potassium phosphate, not potassium chloride. The intended anesthetic was mepivacaine, not bupivacaine. Ascension says the error occurred in its pharmacy, not that four surgeons independently selected the wrong medication. And while serious injuries to all four patients are confirmed, the hospital has not publicly confirmed that all four were paralyzed.

Those distinctions do not make what happened less serious.

They make the real question more important:

How did the same pharmacy medication error make it far enough through a modern hospital’s safety system to reach four separate patients?

What Ascension Saint Thomas Has Actually Confirmed

Ascension Saint Thomas released a more detailed statement on August 21, one week after the incident.

According to the hospital:

• The error occurred on Friday, August 14.
• It occurred in the hospital pharmacy.
• Four joint-replacement patients were affected.
• The intended medication was mepivacaine.
• The medication they received instead was potassium phosphate.
• All four experienced adverse health reactions.
• Hospital leadership reported the incident to state regulators on August 14.
• An internal review determined that no additional patients were affected.

Ascension has described what happened as an “isolated medication error.”

That phrase deserves some care.

The hospital appears to mean that the event was limited to these four patients and that its review found no broader exposure. It should not be interpreted to mean that a single bedside mistake necessarily occurred four separate times.

The exact mechanism has not yet been publicly disclosed.

Potassium Phosphate, Not Potassium Chloride

This is the most important correction to the viral version.

Initial reports relied heavily on information provided by family members and other sources and identified the medication as potassium chloride. Some also identified the intended anesthetic as bupivacaine.

Ascension’s subsequent pharmacy investigation identified the drugs differently: potassium phosphate was substituted for mepivacaine.

That matters because potassium chloride and potassium phosphate are not interchangeable substances.

Potassium chloride is particularly notorious because concentrated KCl has caused fatal medication errors for decades and has been used as part of some lethal-injection protocols. That history produced much of the sensational framing surrounding the Nashville case.

But there is no reason to import that detail into this incident when Ascension says the medication involved was potassium phosphate.

Potassium phosphate is itself a legitimate medical drug.

It is used to replace phosphorus and provide phosphate in certain patients. The FDA-approved labeling for injectable potassium phosphate specifies that it is for intravenous use after dilution or admixture into a larger volume of fluid. The labeling warns that undiluted, bolus or excessively rapid intravenous administration can cause serious cardiac complications.

The problem in Nashville was not that the pharmacy possessed some inherently sinister chemical.

The problem was that a medication intended for a completely different purpose and route apparently reached patients where a local anesthetic was supposed to be.

That is a catastrophic wrong-drug error.

Was Mepivacaine a Normal Drug to Use for Knee Replacement Surgery?

Yes.

Mepivacaine is a local anesthetic used for neuraxial anesthesia, including spinal anesthesia for total knee and hip replacement procedures.

Multiple clinical studies have compared mepivacaine with the longer-acting anesthetic bupivacaine in joint-replacement patients. A systematic review of five studies involving 1,550 patients found that mepivacaine spinal anesthesia was associated with somewhat faster return of motor function and shorter hospital stays than bupivacaine, without significant differences in several other measured outcomes.

In other words, nothing unusual about the intended medication explains this event.

The extraordinary part is what apparently replaced it.

Were All Four Patients Paralyzed?

That has not been established publicly.

Ascension has confirmed adverse reactions involving all four patients but has not released their individual diagnoses, citing patient privacy.

NewsChannel 5’s investigative reporting says at least two patients were left paralyzed. It has also reported that another patient required ventilator support and that additional patients were critically ill.

The most extensively documented case is Glenda Dorton’s.

Dorton, 72, went to Ascension Saint Thomas Midtown for a knee replacement. Her family told local and national reporters that the orthopedic operation itself went successfully, but the medication error associated with her anesthesia caused catastrophic neurological injury.

Her family reported that she experienced burning and itching, lost feeling and movement below her chest, required intensive-care treatment and was diagnosed with paralysis around the T6 level. Her attorney subsequently described her prognosis as serious and her recovery as uncertain.

That supports saying Dorton was paralyzed.

It does not justify converting “four patients were harmed” into “four people were permanently paralyzed.”

Those are different claims.

Why Can a Wrong Potassium Injection Cause Paralysis?

Here, an important scientific distinction is necessary.

There is substantial published medical literature describing catastrophic neurological injuries after potassium chloride was accidentally administered into the epidural or intrathecal space.

There is much less published human evidence specifically involving accidental neuraxial administration of potassium phosphate.

So potassium chloride case reports should not simply be presented as though they document the exact Nashville exposure.

But they show why physicians take accidental exposure of neural tissue to concentrated potassium-containing preparations extremely seriously.

A 2021 review examined 28 reported patients who accidentally received potassium chloride through epidural or intrathecal routes. Twenty-two developed paraplegia, 11 required mechanical ventilation and three died. The circumstances and doses varied considerably, and these were case reports rather than a controlled study, but the pattern demonstrates the potential severity of neuraxial potassium exposure.

One published case involved a 62-year-old patient undergoing hip replacement who accidentally received potassium chloride instead of bupivacaine during spinal anesthesia. He developed severe pain, cramps, paraplegia and pulmonary edema, although aggressive treatment including cerebrospinal-fluid lavage was followed by recovery without permanent injury.

Again, potassium chloride is not potassium phosphate.

The responsible conclusion is narrower: the medical literature establishes that accidentally delivering concentrated potassium-containing medication into neuraxial spaces can produce profound neurological injury. The precise toxicology of the potassium phosphate exposure in the Nashville patients will depend on factors that have not been publicly disclosed, including the product concentration, amount administered and exact route.

Potassium Phosphate Was Already Considered a High-Alert Medication

This is where the story becomes more than an extraordinary medical accident.

The Institute for Safe Medication Practices, or ISMP, includes potassium phosphates injection on its current list of high-alert medications for acute-care hospitals.

“High-alert” does not mean the medication is unusually likely to be administered incorrectly.

It means that when an error occurs, the consequences can be particularly severe.

ISMP recommends additional safeguards for such medications, potentially including standardized storage and preparation, limited access, improved labeling, automated alerts and independent checks where appropriate.

And concentrated-electrolyte errors are not some newly discovered patient-safety problem.

ISMP safety guidance has specifically discussed potassium phosphate alongside other concentrated electrolytes and recommended physical separation of concentrated-electrolyte products in pharmacy storage and compounding areas.

The Joint Commission’s very first Sentinel Event Alert, issued in 1998, concerned fatal potassium chloride medication errors. Those historic incidents frequently involved concentrated potassium being mistaken for another medication because of storage, packaging or selection problems.

That history does not prove that Ascension violated a particular regulation or standard on August 14.

It does mean the general hazard—a high-risk electrolyte being selected or administered instead of another medication—is extremely well known.

The Safeguards Ascension Added Afterward Raise an Obvious Question

Following the incident, Ascension announced three specific changes at its Midtown hospital.

It says it has now implemented:

Isolated medication storage. High-alert medications are being stored in separate, distinctly marked locations.

A mandatory hard stop for scanning alerts. Any alert involving a spinal medication must now be stopped and resolved through independent verification.

Independent dual verification. A second trained pharmacist must perform final visual and physical checks of spinal medications.

Those are sensible corrective measures.

They also create one of the most important unanswered questions in the story:

What protections existed before August 14, and why were they insufficient?

NewsChannel 5 asked essentially that question of Dr. Stephen Eckel, a pharmacy professor at the University of North Carolina.

Discussing measures such as separating high-risk drugs and using verification systems, Eckel said these are practices that should be used in patient care and described the Nashville incident as a reason for hospitals elsewhere to reassess their own systems.

There is a critical evidentiary line here.

The fact that Ascension added safeguards after the incident does not by itself establish that the hospital previously violated a legal requirement, accreditation rule or recognized standard of care.

But the timing makes the previous workflow an obvious subject for regulators.

Investigators will need to determine what safeguards existed, whether they functioned as designed, whether warnings appeared, whether anyone overrode them, and whether the system was capable of detecting the original error at all.

How Could One Error Reach Four Different Patients?

We do not yet know.

And that may ultimately be the most important unanswered question.

Four patients undergoing similar procedures on the same day received the same incorrect medication, according to Ascension.

That pattern reasonably suggests a shared upstream failure, rather than four unrelated clinicians coincidentally making the same selection mistake.

But that is an inference—not a publicly established investigative finding.

Possible questions include:

• Was medication prepared for multiple procedures during the same pharmacy workflow?
• Was the wrong vial selected during preparation?
• Were medications mislabeled after preparation?
• Did visually similar packaging contribute?
• Was barcode scanning used?
• Did a scan produce an alert?
• If so, what happened to that alert?
• Was an independent pharmacist verification already required?
• How did the medication pass from pharmacy preparation through administration without the discrepancy being detected?

Ascension has not publicly answered those questions.

Its corrective measures are revealing because they focus specifically on storage separation, scan alerts and second-pharmacist verification.

But those changes cannot responsibly be reverse-engineered into a definitive explanation for the original failure.

We know where the hospital says the error originated.

We do not yet know exactly how it happened.

This Is Why Medication Safety Is Built Around Systems, Not Just “Being More Careful”

It is tempting after a catastrophic medical error to immediately identify the person who touched the medication last and ask why that person did not simply pay more attention.

Modern patient-safety engineering is built around the recognition that this approach is inadequate.

Humans make mistakes.

A high-reliability system is supposed to make it difficult for one mistake to become a patient injury.

The Agency for Healthcare Research and Quality notes that serious medication errors frequently reveal underlying system weaknesses involving workflow, technology, human-factors engineering and safety culture. Barcode systems and computerized safeguards can reduce risk, but only when they are designed and implemented so that errors are actually intercepted.

That does not mean individual responsibility disappears.

A “just culture” approach distinguishes ordinary human error from risky shortcuts or reckless conduct. Systems are accountable for the environment they create; individuals can still be accountable for their choices.

The American Society of Health-System Pharmacists and American Pharmacists Association made the same point in a joint statement responding to the Nashville case: investigators should identify underlying vulnerabilities before assigning individual blame.

That principle should not become a euphemism for avoiding accountability.

If a required safety check was intentionally ignored, that matters. If the hospital designed a workflow incapable of reliably catching this error, that matters too.

The investigation needs to determine which occurred.

Possibly both.

Why Is the Tennessee Bureau of Investigation Involved?

The incident is no longer only an internal hospital review.

The Tennessee Health Facilities Commission has been investigating the event and has had personnel on site. The commission also informed the Tennessee Bureau of Investigation, which opened an investigation and has described it as active and ongoing. The Health Facilities Commission has additionally been coordinating with the Centers for Medicare & Medicaid Services on patient-safety oversight.

The involvement of the TBI understandably sounds dramatic.

It should not be interpreted as proof that someone committed a crime.

As of this writing, no criminal charge has been publicly announced, and local investigative reporting says there was no indication that the medication mix-up was intentional. Metro Nashville Police and the Davidson County District Attorney’s Office had not announced separate investigations at the time of that reporting.

Tennessee also has unusually recent history surrounding the criminal prosecution of a catastrophic medication error: former Vanderbilt nurse RaDonda Vaught was convicted in 2022 after accidentally administering the paralytic vecuronium instead of midazolam to a patient who died.

That prosecution generated a national debate over where criminal negligence ends and medical error begins.

There is currently no basis for assuming the Ascension case will follow the same path.

Did “Doctors” Cause the Error?

Based on what is publicly established, describing this simply as “doctors injected the wrong drug” is misleading.

Ascension says the medication error occurred in its pharmacy.

Dorton’s family has likewise publicly emphasized that, based on what they were told, they did not blame the surgeon or anesthesiology team for originating the mix-up.

That does not resolve every possible question about the later verification and administration process.

A full medication chain can involve prescribing, pharmacy selection, compounding, labeling, dispensing, transportation, verification and administration.

Investigators will have to establish which defenses existed at each stage and which failed.

Until then, attributing the incident to a particular doctor, nurse, pharmacist or technician would go beyond the evidence.

Why the “Lethal Injection Drug” Headline Should Be Retired

There is an understandable reason that description spread.

Families were initially told or understood that potassium chloride was involved, and potassium chloride has historically been associated with lethal injection.

But once Ascension’s pharmacy review identified potassium phosphate, continuing to package the story around a “lethal injection drug” becomes misleading.

It also distracts from the more consequential story.

This did not need to involve an execution drug to be horrifying.

A recognized high-alert medication intended for carefully controlled intravenous administration was substituted for a local anesthetic used in joint-replacement patients, harming four people and reportedly leaving at least two paralyzed.

That is serious enough without embellishment.

What We Still Do Not Know

Despite the hospital’s August 21 disclosure, several crucial facts remain unresolved.

Ascension has not publicly explained:

• the exact concentration and quantity of potassium phosphate each patient received;
• the precise neuraxial route used in each patient;
• exactly how potassium phosphate was selected instead of mepivacaine;
• whether a single preparation process supplied multiple patients;
• whether the medications or containers looked similar;
• whether barcode scanning produced an alert before administration;
• whether an alert was overridden, bypassed or never generated;
• what verification procedures existed before August 14;
• which employee or employees participated in the preparation and verification process;
• the current medical condition and prognosis of all four patients;
• or what state and federal investigators have independently concluded.

Those aren’t minor details.

They determine whether this was primarily a selection mistake, compounding error, labeling failure, technology failure, procedural failure, staffing problem, policy problem, individual misconduct—or some combination of them.

The Bottom Line

The Tennessee hospital story is not an internet fabrication.

Four joint-replacement patients at Ascension Saint Thomas Hospital Midtown really did receive potassium phosphate instead of the intended anesthetic mepivacaine because of a pharmacy medication error. All four were harmed, and local investigative reporting says at least two were left paralyzed.

But the story became distorted as it went viral.

The hospital says the medication was potassium phosphate, not potassium chloride. The evidence does not establish that four doctors independently made the error. And the medical condition of all four patients has not been publicly disclosed.

Correcting those exaggerations should not minimize what happened.

It should sharpen the scrutiny.

Potassium phosphate was already recognized as a high-alert medication. Concentrated-electrolyte mix-ups have been a known patient-safety hazard for decades. Ascension has now introduced physical separation, mandatory scan-alert stops and dual pharmacist verification for spinal medications.

The central question is therefore no longer merely “How could somebody grab the wrong drug?”

It is:

How did a wrong drug make it through enough layers of a modern hospital medication system to reach four patients before the system stopped it?

Until regulators and investigators answer that question, the most important part of the Ascension Saint Thomas story remains unfinished.

References and Further Reading

Primary and Regulatory Sources

• Ascension Saint Thomas Midtown Update — August 21, 2026 — Ascension’s detailed account identifying potassium phosphate, mepivacaine, four affected patients and the pharmacy as the location of the medication error.

• FDA Prescribing Information: Potassium Phosphates Injection — Official labeling describing intravenous use after dilution and warnings associated with improper administration.

• ISMP List of High-Alert Medications in Acute Care Settings — Lists potassium phosphates injection among medications requiring heightened safeguards.

• ISMP Medication Safety Self Assessment for High-Alert Medications — Includes recommended practices for concentrated electrolytes such as segregated pharmacy storage.

Investigation and Patient Reporting

• NewsChannel 5: Hospital Confirms Pharmacy Error After Drug Mix-Up — Local investigative reporting on Ascension’s confirmation and reported patient outcomes.

• NewsChannel 5: TBI Investigating Catastrophic Nashville Hospital Drug Mix-Up — Reporting on the TBI and Health Facilities Commission investigations and reports that at least two patients were paralyzed.

• NewsChannel 5: Why Weren’t the New Pharmacy Safeguards Already in Place? — Examination of Ascension’s post-incident safeguards and broader medication-safety practices.

• CBS News: Drug Mix-Up at Nashville Hospital Causes Dire Complications in Four Patients — National reporting including comments from Glenda Dorton’s attorney regarding her prognosis.

Medical and Patient-Safety Evidence

• PubMed: Narrative Review of Neuraxial Potassium Chloride Administration Errors — Review of 28 published potassium chloride neuraxial medication errors and their neurological outcomes. These cases involve potassium chloride, not potassium phosphate, and are included as related toxicological evidence rather than direct evidence about the Nashville patients.

• PubMed: Accidental Spinal Potassium Chloride Injection Successfully Treated With Spinal Lavage — Case report involving paraplegia after accidental potassium chloride administration during hip-replacement spinal anesthesia.

• PubMed: Mepivacaine Versus Bupivacaine Spinal Anesthesia for Primary Total Joint Arthroplasty — Systematic review supporting the established use of mepivacaine for neuraxial anesthesia in joint replacement.

• AHRQ PSNet: Medication Errors and Adverse Drug Events — Overview of medication errors, safety barriers and the role of system weaknesses in serious adverse events.

• AHRQ PSNet: Culture of Safety — Explains the “just culture” approach balancing system accountability with individual responsibility.

• ASHP and APhA Joint Statement on the Nashville Medication Error — Professional pharmacy organizations’ response emphasizing investigation of underlying system vulnerabilities before conclusions about individual responsibility.

Editorial currency note: This is an active investigation. Patient conditions, regulatory findings, civil claims or criminal-investigation details may change after publication. The article should be updated as the Tennessee Bureau of Investigation, Tennessee Health Facilities Commission, CMS or Ascension Saint Thomas releases additional verified information.